Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

A Patient-Derived Xenograft Repository Capturing Clinical and Molecular Heterogeneity of Large B-cell Lymphoma.

Blood cancer discovery·2026

Same author

Efficacy and safety of subcutaneous mosunetuzumab plus polatuzumab vedotin in patients with relapsed/refractory large B-cell lymphoma: Japan subgroup analysis of the phase III SUNMO trial.

International journal of clinical oncology·2026

Same author

Lenalidomide plus rituximab for previously untreated advanced follicular lymphoma: the 10-year RELEVANCE trial analysis.

Blood·2026

Same author

Marginal Zone Lymphoma: 2026 Update on Diagnosis and Management.

American journal of hematology·2026

Same author

A patient derived xenograft repository capturing clinical and molecular heterogeneity of large B-cell lymphoma.

bioRxiv : the preprint server for biology·2026

Same author

Approaches to the management of relapsed/refractory mantle cell lymphoma: navigating an increasingly complex therapeutic landscape.

Expert review of hematology·2026

Same journal

Author response to Zhang and Chen.

British journal of haematology·2026

Same journal

Response-adapted chimeric antigen receptor T cell (CAR-T)-sparing consolidation radiotherapy in high-risk large B-cell lymphoma (LBCL): Results of the prospective RESTART protocol.

British journal of haematology·2026

Same journal

Prospective, multicentre phase II study to evaluate the clinical benefit of reduced-dose lenalidomide and dexamethasone based on frailty stratification in elderly, unfit patients with newly diagnosed multiple myeloma.

British journal of haematology·2026

Same journal

Real-world effectiveness and safety of acalabrutinib in chronic lymphocytic leukaemia: Multicentre experience.

British journal of haematology·2026

Same journal

Novel germline GATA1s-generating variant associates with somatic STAG2 variants in hypoplastic myelodysplastic neoplasm.

British journal of haematology·2026

Same journal

The Endothelial Activation and Stress Index (EASIX) at diagnosis is associated with survival in primary central nervous system lymphoma.

British journal of haematology·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Apr 19, 2026

Enhancing Tumor Content through Tumor Macrodissection

Enhancing Tumor Content through Tumor Macrodissection

Published on: February 12, 2022

A clinician's guide to double hit lymphomas.

Chan Yoon Cheah¹, Yasuhiro Oki, Jason R Westin

¹Department of Lymphoma/Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX, USA.

British Journal of Haematology

|December 23, 2014

Summary

This summary is machine-generated.

Double hit lymphomas (DHL) are aggressive B-cell cancers. This review covers diagnosis, prognostic factors, and optimal therapies, including novel treatments for this challenging disease.

Keywords:

B-cell lymphoma unclassifiable MYC diffuse large B-cell lymphoma double-hit lymphoma triple-hit lymphoma

More Related Videos

Multiplexed Fluorescent Immunohistochemical Staining, Imaging, and Analysis in Histological Samples of Lymphoma

Multiplexed Fluorescent Immunohistochemical Staining, Imaging, and Analysis in Histological Samples of Lymphoma

Published on: January 9, 2019

Dual Immunofluorescence of γH2AX and 53BP1 in Human Peripheral Lymphocytes

Dual Immunofluorescence of γH2AX and 53BP1 in Human Peripheral Lymphocytes

Published on: July 14, 2023

Related Experiment Videos

Last Updated: Apr 19, 2026

Enhancing Tumor Content through Tumor Macrodissection

Enhancing Tumor Content through Tumor Macrodissection

Published on: February 12, 2022

Multiplexed Fluorescent Immunohistochemical Staining, Imaging, and Analysis in Histological Samples of Lymphoma

Multiplexed Fluorescent Immunohistochemical Staining, Imaging, and Analysis in Histological Samples of Lymphoma

Published on: January 9, 2019

Dual Immunofluorescence of γH2AX and 53BP1 in Human Peripheral Lymphocytes

Dual Immunofluorescence of γH2AX and 53BP1 in Human Peripheral Lymphocytes

Published on: July 14, 2023

Area of Science:

Hematology
Oncology
Genetics

Background:

Double hit lymphomas (DHL) are aggressive B-cell malignancies.
Characterized by MYC rearrangements with BCL2 and/or BCL6.
Includes MYC/BCL2 protein co-expressing lymphomas, representing 30-40% of diffuse large B-cell lymphomas.

Purpose of the Study:

Provide a comprehensive overview of DHL for clinicians.
Discuss diagnosis, prognostic factors, and optimal therapeutic strategies.
Highlight emerging therapies for aggressive B-cell lymphomas.

Main Methods:

Review of current literature and clinical evidence.
Discussion of diagnostic criteria and classification.
Analysis of therapeutic options and emerging treatments.

Main Results:

DHL definition expanded to include protein co-expression.
5-10% of diffuse large B-cell lymphomas are cytogenetically DHL.
30-40% of diffuse large B-cell lymphomas show MYC/BCL2 protein co-expression.

Conclusions:

Optimal therapy for DHL requires careful consideration of induction regimens, CNS prophylaxis, and stem cell transplantation.
Relapsed or refractory disease management is critical.
Novel therapeutic agents show promise for treating this aggressive malignancy.